PP
ABCL icon

PDT Partners’s AbCellera Biologics ABCL Stock Holding History

PDT Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-64,304
Closed -$143K – 678
2025
Q1 		$143K Hold
64,304
– – 0.01% 702
2024
Q4 		$188K Hold
64,304
– – 0.02% 664
2024
Q3 		$167K Sell
64,304
-173,884
-73% -$482K 0.01% 672
2024
Q2 		$705K Sell
238,188
-9,290
-4% -$35.2K 0.07% 408
2024
Q1 		$1.12M Buy
247,478
+100
+0% +$510 0.11% 310
2023
Q4 		$1.41M Buy
247,378
+37,302
+18% +$173K 0.16% 226
2023
Q3 		$966K Buy
210,076
+125,612
+149% +$764K 0.12% 291
2023
Q2 		$546K Hold
84,464
– – 0.08% 364
2023
Q1 		$637K Buy
+84,464
New +$767K 0.09% 347
2022
Q4 		– Sell
-96,417
Closed -$954K – 603
2022
Q3 		$954K Sell
96,417
-44,975
-32% -$493K 0.14% 233
2022
Q2 		$1.51M Buy
+141,392
New +$1.2M 0.13% 246

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PDT Partners's ABCL Position: Q2 2025 in Review

PDT Partners sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 64,304 shares — an estimated $143K sold.

PDT Partners first reported a position in ABCL in Q2 2022 and held it in 11 quarters. The position peaked at $1.51M in Q2 2022. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

  • PDT Partners reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
  • PDT Partners sold 64,304 AbCellera Biologics shares in Q2 2025, an estimated $143K.
  • PDT Partners first reported a position in AbCellera Biologics in Q2 2022 and held it in 11 quarters.
  • PDT Partners's AbCellera Biologics position peaked at $1.51M in Q2 2022.
  • 128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on PDT Partners's 13F filing for Q2 2025, filed 14 Aug 2025.